{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T15:17:16Z","timestamp":1767453436808},"reference-count":19,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1016\/j.vaccine.2009.12.080","type":"journal-article","created":{"date-parts":[[2010,1,9]],"date-time":"2010-01-09T09:26:22Z","timestamp":1263029182000},"page":"2436-2441","source":"Crossref","is-referenced-by-count":12,"title":["Immunogenicity of an inactivated Japanese encephalitis vaccine (JE-VAX) in humans over 20 years at USAMRIID: Using PRNT50 as an endpoint for immunogenicity"],"prefix":"10.1016","volume":"28","author":[{"given":"Ronald B.","family":"Reisler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise K.","family":"Danner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul H.","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2009.12.080_bib1","series-title":"Vaccines","first-page":"311","article-title":"Japanese encephalitis vaccines","author":"Halstead","year":"2008"},{"key":"10.1016\/j.vaccine.2009.12.080_bib2","series-title":"Clinical virology","first-page":"1173","article-title":"Arthropod-borne flaviviruses","author":"Petersen","year":"2009"},{"key":"10.1016\/j.vaccine.2009.12.080_bib3","doi-asserted-by":"crossref","first-page":"974","DOI":"10.4269\/ajtmh.1975.24.974","article-title":"The virulence to man of Japanese encephalitis virus in Thailand","volume":"24","author":"Benenson","year":"1975","journal-title":"Am J Trop Med Hyg"},{"issue":"RR-01","key":"10.1016\/j.vaccine.2009.12.080_bib4","first-page":"1","article-title":"Inactivated Japanese encephalitis virus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"42","author":"CDC","year":"1993","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2009.12.080_bib5","first-page":"241","volume":"80","author":"WHO","year":"2005","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2009.12.080_bib6","series-title":"CDC health information for international travel 2010","author":"Centers for Disease Control and Prevention","year":"2009"},{"key":"10.1016\/j.vaccine.2009.12.080_bib7","first-page":"737","article-title":"Japanese encephalitis among three U.S. travelers returning from Asia, 2003\u20132008","volume":"58","author":"Centers for Disease Control and Prevention","year":"2009","journal-title":"MMWR"},{"key":"10.1016\/j.vaccine.2009.12.080_bib8","doi-asserted-by":"crossref","first-page":"593","DOI":"10.4269\/ajtmh.1988.39.593","article-title":"Isolation of a newly recognized Bunyawera serogroup virus from a febrile human in Panama","volume":"39","author":"Mangiafico","year":"1988","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2009.12.080_bib9","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1016\/j.vaccine.2005.12.055","article-title":"Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine","volume":"24","author":"Hepburn","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.12.080_bib10","unstructured":"SAS Institute Incorporated, 2009. Cary, NC."},{"key":"10.1016\/j.vaccine.2009.12.080_bib11","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/S0140-6736(07)61780-2","article-title":"Safety and immunogenicity of a Vero-cell-derived inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomized controlled trial","volume":"370","author":"Tauber","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2009.12.080_bib12","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1093\/infdis\/171.4.1074","article-title":"Japanese encephalitis vaccine: persistence of antibody up to 3 years after a three-dose primary series","volume":"171","author":"Gambel","year":"1995","journal-title":"JID"},{"key":"10.1016\/j.vaccine.2009.12.080_bib13","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4269\/ajtmh.1999.61.288","article-title":"Japanese encephalitis vaccine (inactivated, Biken) in US soldiers: immunogenicity and safety of vaccine administered in two dosing regimens","volume":"61","author":"Defraites","year":"1999","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2009.12.080_bib14","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1442-200X.1988.tb02516.x","article-title":"Japanese encephalitis vaccine","volume":"30","author":"Oya","year":"1988","journal-title":"Acta Paediatr Jpn"},{"key":"10.1016\/j.vaccine.2009.12.080_bib15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0264-410X(00)00038-4","article-title":"Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines","volume":"18","author":"Markoff","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.12.080_bib16","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1016\/j.vaccine.2007.05.034","article-title":"WHO informal consultation on the scientific basis of specifications for production and control of inactivated Japanese encephalitis vaccines for human use, Geneva, Switzerland, 1\u20132 June 2006","volume":"25","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.12.080_bib17","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1016\/j.vaccine.2005.07.002","article-title":"Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2\u20133 September, 2004","volume":"23","author":"Hombach","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2009.12.080_bib18","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/vim.2008.0007","article-title":"Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses","volume":"21","author":"Roehrig","year":"2008","journal-title":"Viral Immunol"},{"key":"10.1016\/j.vaccine.2009.12.080_bib19","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1128\/JVI.73.1.783-786.1999","article-title":"New mouse model for dengue virus vaccine testing","volume":"73","author":"Johnson","year":"1999","journal-title":"J Virol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10000162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10000162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T15:55:12Z","timestamp":1590508512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X10000162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S0264410X10000162"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2009.12.080","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}